A number of research firms have changed their ratings and price targets for ACADIA Pharmaceuticals (NASDAQ: ACAD):
- 11/6/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group from $36.00 to $38.00. They now have a “buy” rating on the stock.
- 11/5/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $36.00 to $38.00. They now have an “outperform” rating on the stock.
- 11/4/2026 – ACADIA Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/27/2026 – ACADIA Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/19/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $35.00 price target on the stock.
- 10/19/2026 – ACADIA Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/13/2026 – ACADIA Pharmaceuticals was downgraded by UBS Group from “buy” to “neutral”. They now have a $23.00 price target on the stock, down from $49.00.
- 10/11/2026 – ACADIA Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/8/2026 – ACADIA Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $37.00 to $36.00. They now have an “outperform” rating on the stock.
- 10/3/2026 – ACADIA Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/28/2026 – ACADIA Pharmaceuticals was given a new $33.00 price target by William Blair.
- 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Deutsche Bank Aktiengesellschaft from $38.00 to $31.00. They now have a “buy” rating on the stock.
- 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Needham & Company LLC from $41.00 to $35.00. They now have a “buy” rating on the stock.
- 9/25/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Citigroup. They now have a $33.00 price target on the stock, down from $40.00.
- 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by HC Wainwright from $37.00 to $33.00. They now have a “buy” rating on the stock.
- 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Citizens Jmp from $36.00 to $33.00. They now have a “market outperform” rating on the stock.
- 9/24/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
- 9/24/2026 – ACADIA Pharmaceuticals had its price target lowered by BMO Capital Markets from $36.00 to $34.00. They now have an “outperform” rating on the stock.
- 9/24/2026 – ACADIA Pharmaceuticals had its price target lowered by Citigroup from $40.00 to $33.00. They now have a “buy” rating on the stock.
- 9/24/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $41.00 price target on the stock.
- 9/23/2026 – ACADIA Pharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer.
ACADIA Pharmaceuticals Trading Down 22.3%
NASDAQ:ACAD opened at $16.50 on Tuesday. ACADIA Pharmaceuticals Inc. has a 12 month low of $15.85 and a 12 month high of $30.96. The firm has a fifty day simple moving average of $22.61 and a 200-day simple moving average of $23.54. The company has a market capitalization of $2.84 billion, a P/E ratio of 7.82 and a beta of 0.87.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.12% and a net margin of 30.13%. The company had revenue of $342.30 million during the quarter, compared to analyst estimates of $332.58 million. During the same quarter last year, the business posted $0.42 EPS. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.74 EPS for the current year.
Insider Activity
In related news, EVP Mark Schneyer sold 3,321 shares of ACADIA Pharmaceuticals stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares of the company’s stock, valued at $1,489,203.36. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 26.20% of the stock is currently owned by insiders.
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations.
Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.
Read More
- Five stocks we like better than ACADIA Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
